Single Low-dose Suprachoroidal Triamcinolone Acetonide Injection in Macular Edema Secondary to Noninfectious Posterior Uveitis

PURPOSE: The purpose was to study the anatomical and functional outcome following single low -dose suprachoroidal triamcinolone acetonide (LD-SCTA) (2 mg) injection in noninfectious posterior uveitis. METHODS: Eleven patients with macular edema (ME) more than 280 mu secondary to noninfectious uveitis were included in the study. A single LD-SCTA (0.5 ml) injection was performed in the study eye with the help of a novel suprachoroidal microneedle (Pricon, Iscon Surgicals, Jodhpur, Rajasthan, India). The study parameters were noted at 4 and 12 weeks post LD-SCTA injection. RESULTS: Ten of 11 patients had a significant decrease in central macular thickness (CMT). The mean CMT measurement at baseline was 513.6 +/- 191.73 mu m for the 10 patients who responded to the treatment, which reduced significantly to 265.1 +/- 34.72 mu m (P < 0.003) and 260.6 +/- 34.72 <mu>m (P < 0.002) at 4 and 12 weeks, respectively. The mean best -corrected visual acuity (BCVA) at baseline was 0.84 +/- 0.41 logMAR unit which improved to 0.52 +/- 0.33 (P < 0.001) and 0.25 +/- 0.22 (P < 0.000) at weeks 4 and 12, respectively. The mean intraocular pressure at baseline recorded was 16.36 +/- 2.97 mmHg, 19.45 +/- 4.80 mmHg (P = 0.06) at 4 weeks, and 17.27 +/- 2.53 mmHg (P = 0.35) at 12 weeks. One eye which did not respond to LD-SCTA was a case of recurrent Vogt-Koyanagi-Harada disease. CONCLUSION: Single LD-SCTA injection is efficacious in reducing CMT in ME, improving BCVA, and controlling the inflammation in noninfectious posterior uveitis. LD-SCTA can be used as a first -line therapy in noninfectious uveitis over other routes of steroid administration with a favorable outcome and safety profile.